Single Biggest Cancer Dictionary in the World

What is anti-BCMA/GPRC5D/CD3 trispecific antibody JNJ-79635322?

Pronunciation: /ˈænˌti bcma* gprc* faɪv di ˈsiˈdi θri trispecific* ˈæntɪˌbɑdi jnj* seventy-nine* ˈmɪljən, sɪks ˈhənərd ənd ˈθərdiˌfaɪv ˈθaʊzənd, θri ˈhənərd ənd tˈwɛntiˌtu/

anti-BCMA/GPRC5D/CD3 trispecific antibody JNJ-79635322

Definition

A T-cell engager and trispecific antibody targeting the two tumor-associated antigens (TAAs) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and human G-protein coupled receptor family C group 5 member D (GPRC5D), and the T-cell surface antigen CD3, with potential immunomodulating and antineoplastic activities. Upon administration, anti-BCMA/GPRC5D/CD3 trispecific antibody JNJ-79635322 simultaneously targets and binds to BCMA and GPRC5D expressed on tumor cells, and CD3 expressed on T cells. The resulting cross-linkage activates and redirects CTLs to GPRC5D- and BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival. GPRC5D is overexpressed on certain tumors, including multiple myeloma, while minimally expressed on normal, healthy cells, and plays a key role in tumor cell proliferation.